Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D06XDS
|
||||
| Former ID |
DIB005747
|
||||
| Drug Name |
GSK-1070806
|
||||
| Synonyms |
Anti-IL-18 monoclonal antibody (intravenous, inflammatory bowel disease), GSK
|
||||
| Drug Type |
Antibody
|
||||
| Indication | Type 2 diabetes [ICD9: 250; ICD10:E11] | Phase 2 | [1] | ||
| Company |
GlaxoSmithKline
|
||||
| Target and Pathway | |||||
| Target(s) | Interleukin-18 | Target Info | [2] | ||
| KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
| NOD-like receptor signaling pathway | |||||
| Cytosolic DNA-sensing pathway | |||||
| Salmonella infection | |||||
| Legionellosis | |||||
| African trypanosomiasis | |||||
| Malaria | |||||
| Tuberculosis | |||||
| Influenza A | |||||
| Inflammatory bowel disease (IBD) | |||||
| Rheumatoid arthritis | |||||
| NetPath Pathway | IL4 Signaling Pathway | ||||
| PANTHER Pathway | Interleukin signaling pathway | ||||
| Toll receptor signaling pathway | |||||
| Pathway Interaction Database | IL27-mediated signaling events | ||||
| IL12-mediated signaling events | |||||
| IL23-mediated signaling events | |||||
| Cellular roles of Anthrax toxin | |||||
| IL12 signaling mediated by STAT4 | |||||
| Reactome | Interleukin-1 processing | ||||
| WikiPathways | Hypertrophy Model | ||||
| IL1 and megakaryotyces in obesity | |||||
| Corticotropin-releasing hormone | |||||
| NOD pathway | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01648153) Investigate the Efficacy and Safety of GSK1070806 in Obese Subjects With T2DM. U.S. National Institutes of Health. | ||||
| REF 2 | Targeting the IL-1 family members in skin inflammation. Curr Opin Investig Drugs. 2010 November; 11(11): 1211-1220. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.